All Stories

  1. Impact of anti-T-lymphocyte globulin dosing on graft versus host disease in matched sibling peripheral blood stem cell transplantation

    Article • British Journal of Pharmacology, January 2026, Springer Science + Business Media

    Radwan Massoud

  2. Multicenter validation of the newly developed Concise Objectifiable Risk Evaluation (CORE) score also confirms its ability to complement the Hematopoietic Cell Comorbidity Index (HCT-CI)

    Article • British Journal of Pharmacology, December 2025, Springer Science + Business Media

    Radwan Massoud

  3. Sequential versus standard conditioning in untreated MDS patients with blasts undergoing allogeneic HSCT

    Article • British Journal of Pharmacology, October 2025, Springer Science + Business Media

    Radwan Massoud

  4. Different clearance of KITD816V mutation and tryptase levels after haematopoietic cell transplantation in patients with systemic mastocytosis with associated haematological neoplasm

    Article • British Journal of Haematology, June 2025, Wiley

    Radwan Massoud

  5. Lower incidence of chronic graft-versus-host disease after ruxolitinib plus extracorporeal photopheresis versus ruxolitinib alone in steroid-refractory acute graft-versus-host disease following allogeneic stem cell transplantation

    Article • Haematologica, March 2025, Ferrata Storti Foundation (Haematologica)

    Radwan Massoud

  6. Clearance of Driver Mutations after Transplantation for Myelofibrosis

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, January 2025, New England Journal of Medicine (NEJM/MMS)

    Radwan Massoud

  7. Sequential Conditioning With FLAMSA Does Not Improve Outcomes of Allogeneic Stem Cell Transplantation in Chronic Myelomonocytic Leukemia Patients

    Article • Transplantation and Cellular Therapy, January 2025, Elsevier

    Radwan Massoud

  8. Clinical and Immune Effects of Peri‐Transplantation JAK Inhibition for Myelofibrosis

    Article • American Journal of Hematology, November 2024, Wiley

    Radwan Massoud

  9. Comparable Results Between 8 and 12 Gray TBI in Combination With Fludarabine and Post‐Transplant Cyclophosphamide in MRD‐Negative but Not in MRD‐Positive Acute Lymphoblastic Leukemia Patients Transplanted in First Compl...

    Article • European Journal Of Haematology, September 2024, Wiley

    Radwan Massoud

  10. Anti-T-lymphocyte globulin (ATLG) compared to post-transplant cyclophosphamide as GvHD prophylaxis in ALL patients undergoing allogeneic stem cell transplantation

    Article • British Journal of Pharmacology, June 2024, Springer Science + Business Media

    Radwan Massoud

  11. Graft-versus-host disease and impact on relapse in myelofibrosis undergoing hematopoietic stem cell transplantation

    Article • British Journal of Pharmacology, February 2024, Springer Science + Business Media

    Radwan Massoud

  12. Development and Validation of a Concise Objectifiable Risk Evaluation Score for Non-Relapse Mortality after Allogeneic Hematopoietic Stem Cell Transplantation

    Article • Cancers, January 2024, MDPI AG

    Radwan Massoud

  13. Peri-transplant flow-MRD assessment of cells with leukemic stem cells (LSC) associated phenotype in AML patients undergoing allogeneic stem cell transplantation in CR

    Article • Leukemia, January 2024, Springer Science + Business Media

    Radwan Massoud

  14. Allogeneic hematopoetic stem cell transplant for patients with refractory T‐Cell lymphomas

    Article • European Journal Of Haematology, October 2023, Wiley

    Radwan Massoud

  15. Haploidentical stem cell transplantation with post-transplant cyclophosphamide challenges and outcome from a tertiary care center in Lebanon

    Article • Frontiers in Transplantation, June 2023, Frontiers

    Radwan Massoud

  16. Spleen volume and length determined by computed tomography impact outcome after allogeneic stem cell transplantation for myelofibrosis

    Article • British Journal of Pharmacology, March 2023, Springer Science + Business Media

    Radwan Massoud

  17. Individualized busulfan dosing improves outcomes compared to fixed‐dose administration in pre‐transplant minimal residual disease‐positive acute myeloid leukemia patients with intermediate‐risk undergoing allogeneic stem cell transplantation in CR...

    Article • European Journal Of Haematology, December 2022, Wiley

    Radwan Massoud

  18. Impact of Anti-T-lymphocyte globulin dosing on GVHD and Immune reconstitution in matched unrelated myeloablative peripheral blood stem cell transplantation

    Article • British Journal of Pharmacology, July 2022, Springer Science + Business Media

    Radwan Massoud

  19. Post-Transplantation Day +100 Minimal Residual Disease Detection Rather Than Mixed Chimerism Predicts Relapses after Allogeneic Stem Cell Transplantation for Intermediate-Risk Acute Myelogenous Leukemia Patients Undergoing Transplantation in Complete R...

    Article • Transplantation and Cellular Therapy, July 2022, Elsevier

    Radwan Massoud

  20. Post-Transplantation Multicolored Flow Cytometry–Minimal Residual Disease Status on Day 100 Predicts Outcomes for Patients With Refractory Acute Myeloid Leukemia

    Article • Transplantation and Cellular Therapy, May 2022, Elsevier

    Radwan Massoud

  21. Antibody response after vaccination against SARS-CoV-2 in adults with hematological malignancies: a systematic review and meta-analysis

    Article • Haematologica, December 2021, Ferrata Storti Foundation (Haematologica)

    Radwan Massoud

  22. Enhanced Immune Reconstitution of γδ T Cells after Allogeneic Stem Cell Transplantation Overcomes the Negative Impact of Pretransplantation Minimal Residual Disease-Positive Status in Patients with Acute Myelogenous Leukemia

    Article • Transplantation and Cellular Therapy, October 2021, Elsevier

    Radwan Massoud

  23. Risk adapted therapeutic strategy in newly diagnosed acute myeloid leukemia: Refining the outcomes of ELN 2017 intermediate-risk patients

    Article • Leukemia Research, June 2021, Elsevier

    Radwan Massoud

  24. A Pin1/PML/P53 axis activated by retinoic acid in <i>NPM-1c</i> acute myeloid leukemia

    Article • Haematologica, May 2021, Ferrata Storti Foundation (Haematologica)

    Radwan Massoud

  25. Comparison of immune reconstitution between anti-T-lymphocyte globulin and posttransplant cyclophosphamide as acute graft-versus-host disease prophylaxis in allogeneic myeloablative peripheral blood stem cell transplantation

    Article • Haematologica, April 2021, Ferrata Storti Foundation (Haematologica)

    Radwan Massoud

  26. Allogeneic stem cell transplantation in acute leukemia patients after COVID-19 infection

    Article • British Journal of Pharmacology, February 2021, Springer Science + Business Media

    Radwan Massoud

  27. Antibody Response to COVID-19 Vaccination in Adults with Haematological Malignancies: A Systematic Review and Meta-Analysis

    Article • SSRN Electronic Journal, January 2021, Elsevier

    Radwan Massoud

  28. Impact of Adding Antithymocyte Globulin to Posttransplantation Cyclophosphamide in Haploidentical Stem-Cell Transplantation

    Article • Clinical Lymphoma Myeloma & Leukemia, April 2020, Elsevier

    Radwan Massoud

  29. The role of candidate genetic polymorphisms in the interaction between voriconazole and cyclosporine in patients undergoing allogeneic hematopoietic cell transplantation: An explorative study

    Article • Current Research in Translational Medicine, April 2020, Elsevier

    Radwan Massoud

  30. Safety and efficacy of four cycles of Brentuximab Vedotin as consolidation after autologous peripheral stem cell transplantation in relapsed/refractory Hodgkin lymphoma

    Article • Leukemia & Lymphoma, February 2020, Taylor & Francis

    Radwan Massoud

  31. Assessment of Caries Index and Fluoride Intake in a Pediatric Middle Eastern Population

    Article • The Journal of Contemporary Dental Practice, January 2020, Jaypee Brothers Medical Publishing

    Radwan Massoud

  32. Impact of the Conditioning Regimen Dose Intensity Before Autologous Stem Cell Transplantation on the Pulmonary Function Test Abnormalities in Patients With Lymphoma and Multiple Myeloma: Single Center Experience

    Article • Clinical Lymphoma Myeloma & Leukemia, October 2019, Elsevier

    Radwan Massoud

  33. Efficacy and Feasibility of Sorafenib as a Maintenance Agent After Allogeneic Hematopoietic Stem Cell Transplantation for Fms-like Tyrosine Kinase 3 Mutated Acute Myeloid Leukemia: An Update

    Article • Clinical Lymphoma Myeloma & Leukemia, August 2019, Elsevier

    Radwan Massoud

  34. Mutant H3 histones drive human pre-leukemic hematopoietic stem cell expansion and promote leukemic aggressiveness

    Article • Nature Communications, June 2019, Springer Science + Business Media

    Radwan Massoud

  35. Haploidentical related donor allogeneic hematopoietic stem cell transplantation for patient aged older than 76 years with refractory acute myeloid leukemia

    Article • Hematology/Oncology and Stem Cell Therapy, December 2018, Elsevier

    Radwan Massoud, Souha Kanj

  36. Feasibility of Venetoclax-based combinations for adult patients with acute myeloid leukemia relapsing after allogenic stem cell transplantation

    Article • British Journal of Pharmacology, October 2018, Springer Science + Business Media

    Radwan Massoud, Souha Kanj

  37. Site specific diagnostic yield of endoscopic biopsies in Gastrointestinal Graft-versus-Host Disease: A tertiary care Center experience

    Article • Current Research in Translational Medicine, September 2018, Elsevier

    Radwan Massoud

  38. Feasibility of the Combination of Venetoclax and Asparaginase-based Chemotherapy for Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia

    Article • August 2018, Elsevier

    Radwan Massoud, Souha Kanj

  39. Thiotepa 10 mg/kg seems superior to Thiotepa 5 mg/kg in the TBF conditioning regimen in patients undergoing allogeneic stem cell transplantation

    Article • Clinical Lymphoma Myeloma & Leukemia, March 2018, Elsevier

    Radwan Massoud

  40. Progressive multifocal leukoencephalopathy in patients receiving rituximab and cyclophosphamide after haplo-identical T-cell replete transplantation and review of the literature

    Article • Current Research in Translational Medicine, November 2017, Elsevier

    Radwan Massoud, Souha Kanj

  41. Cytomegalovirus reactivation in lymphoma and myeloma patients undergoing autologous peripheral blood stem cell transplantation

    Article • Journal of Clinical Virology, October 2017, Elsevier

    Radwan Massoud, Souha Kanj

  42. Dynamics of molecular response in AML patients with NPM1 and FLT3 mutations undergoing allogeneic stem cell transplant

    Article • British Journal of Pharmacology, June 2017, Nature

    Radwan Massoud

  43. Trends in hematopoietic stem cell transplant activity in Lebanon

    Article • Hematology/Oncology and Stem Cell Therapy, June 2017, Elsevier

    Radwan Massoud

  44. Nivolumab salvage therapy before or after allogeneic stem cell transplantation in Hodgkin lymphoma

    Article • British Journal of Pharmacology, April 2017, Nature

    Radwan Massoud

  45. Efficacy and feasibility of sorafenib as a maintenance agent after allogeneic hematopoietic stem cell transplantation for Fms-like tyrosine kinase 3-mutated acute myeloid leukemia

    Article • Cancer, April 2017, Wiley

    Radwan Massoud

  46. Low-dose 5-azacytidine as preventive therapy for relapse of AML and MDS following allogeneic HCT

    Article • British Journal of Pharmacology, April 2017, Nature

    Radwan Massoud

  47. Bendamustine as a bridge to allogeneic transplant in relapsed/refractory Hodgkin lymphoma patients who failed salvage brentuximab vedotin postautologous peripheral blood stem cell transplantation

    Article • Leukemia & Lymphoma, March 2017, Taylor & Francis

    Radwan Massoud

  48. Hyper-CVAD Compared With BFM-like Chemotherapy for the Treatment of Adult Acute Lymphoblastic Leukemia. A Retrospective Single-Center Analysis

    Article • Clinical Lymphoma Myeloma & Leukemia, March 2017, Elsevier

    Radwan Massoud

  49. Post Transplant Brentuximab Maintenance Appears more Effective than Post Transplant Salvage Brentuximab for Relapsed /Refractory Hodgkin Lymphoma

    Article • Clinical Lymphoma Myeloma & Leukemia, September 2016, Elsevier

    Radwan Massoud

  50. Dynamics of Molecular Response in AML Patients with NPM1 and FLT3 Mutations Undergoing Allogeneic Stem Cell Transplant

    Article • Clinical Lymphoma Myeloma & Leukemia, September 2016, Elsevier

    Radwan Massoud

  51. Incidence of Cytomegalovirus (CMV) Reactivation after Autologous Peripheral Blood Stem Cell Transplantation (ASCT) in 324 Patients with Multiple Myeloma and Lymphoma: a Single-Center Study at the American University of Beirut Medical Center (AUBMC)

    Article • Clinical Lymphoma Myeloma & Leukemia, September 2016, Elsevier

    Radwan Massoud